Press releases

ObsEva SA to Participate in Upcoming Investor Conferences

May 16, 2019

Geneva, Switzerland and Boston, MA – May 16, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that Company Management will be participating in three upcoming investor conferences.

  • The RBC Capital Markets Healthcare Conference taking place in New York, May 21-22. ObsEva will present on Wednesday, May 22 at 8 a.m. Eastern Time (ET).
  • The Jefferies Healthcare Conference taking place in New York June 4-7.  ObsEva will present on June 6at 8 a.m. Eastern Time (ET).
  • The BMO Prescriptions for Success Healthcare Conference taking place in New York June 25.  ObsEva will present on Tuesday, June 25 at 4:20 p.m. Eastern Time (ET).

Conference presentations will be webcast, and available in the “Investors” section of ObsEva’s website www.ObsEva.com.

About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

For further information, please contact:

Media Contact Switzerland and Europe:

Christophe Lamps Dynamics Group

cla@dynamicsgroup.ch
+41 22 308 6220 Office
+41 79 476 26 87 Mobile

Media Contact U.S.:

Marion Janic RooneyPartners LLC

mjanic@rooneyco.com
+1 212 223 4017 Office
+1 646 537 5649 Mobile

CEO Office Contact:

Shauna Dillon

Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:

Mario Corso

Senior Director, Investor Relations

mario.corso@obseva.com
+1 857 972 9347 Office
+1 781 366 5726 Mobile

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue